Lotus Pharmaceutical Co., Ltd. · TWSE:1795
Lotus Pharmaceutical — Q1 2026 Earnings Presentation
16 slides from Lotus Pharmaceutical's earnings presentation, May 15, 2026
Slide 1: Lotus Pharmaceutical 1Q26 Financial Results
Lotus Pharmaceutical 1Q26 Financial Results 15 May 2026
Slide 2: Safe Harbor Statement
INTRODUCTION 2 Safe Harbor Statement Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward looking statements are no
Slide 3: Agenda
3 Agenda 1. 1Q26 BUSINESS HIGHLIGHTS 2. 1Q26 FINANCIAL RESULTS 3. LOTUS BUSINESS UPDATE
Slide 4: Business Highlights
01 BUSINESS HIGHLIGHTS
Slide 5: 1Q26 Revenue Reached Record Quarterly High
5 1Q26 Revenue Reached Record Quarterly High Revenue EBITDA Deals Update NT$8,644mn NT$2,654mn (+83% YoY) (+24% YoY) ➢ M&A: Acquisition of Sandoz’s Philippines business ➢ Keytruda biosimilar (APAC) ➢ SLX-100 (Global) Adj. Net Profit Adj. EPS NT$698mn NT$2.69 (-51% YoY) (-51% YoY)
Slide 6: 1Q26 Pipeline Updates
6 1Q26 PIPELINE UPDATES Filing Approval Launches 25 Submissions 20 Approvals 221 SKUs • 3 505(b)(2) • 1 505(b)(2) • 1 NCE • 4 NCE • 1 NCE • 220 Complex Gx • 2 Biosimilar • 18 Complex Gx • 16 Complex Gx Key Filings Key Approvals Key Launches LP757 (Cabozantinib) (US), Carfilzomib (KR), Palbociclib (E
Slide 7: YTD Licensing and M&A Agreements
7 YTD Licensing and M&A Agreements Lotus becomes Alvogen and Solaxa Lotus entered into an commercialisation entered into license agreement to acquire partner for agreement for the Sandoz AG’s Formycon's development and Philippines business. Keytruda® biosimilar commercialisation of The acquired port
Slide 8: Lotus Pipeline Overview
Lotus Pipeline Overview 8 Therapeutic Areas Specialty Product Pipeline with 137 projects targeting US$120bn+ market Others 14% Oncology & Immunology 38% R&D • Total Addressable Market size of 63 US$50bn+ Cardiovascular 9% • 505(b)(2) NDA Filing for LP757 (Cabozantinib) (Feb 2026) • Received TFDA app
Slide 9: Financial Information
02 FINANCIAL INFORMATION
Slide 10: 1Q26 Financial Results
10 1Q26 Financial Results (in NTD millions, except for EPS) 1Q26 Results Key Financials 26’Q1 25’Q1 YoY Consolidated Revenue 8,644 4,730 +82.8% • Reported Revenue increased by 83% YoY, mainly driven by Cost of Goods (4,259) (1,814) +134.7% consolidation of Alvogen and B2B launches of Nintedanib & Gr
Slide 11: 1Q26 Revenue +83% YoY
11 1Q26 Revenue +83% YoY US +83% YoY 3,000 NT$8,644mn B2B 784 Asia NT$4,730mn z 87 24 33 +156% YoY -14 +408% YoY z +5% YoY 1Q25 KR TW SEA RoA B2B US 1Q26
Slide 12: Diversification Across Therapies and Markets
12 Diversification Across Therapies and Markets Diversified Portfolio Revenue Breakdown YTD 1Q26 Revenue Breakdown by TA Cardiovascular 4% 4% Endocrinology Primary Care /Diabetes & Lifestyle* 31% US 12% Other 57% Therapeutic RoW Gx 84% Areas RoA Branded SEA 11% TW Oncology & 1% KR Central 5% 15% Ner
Slide 13: Healthy Operating Cash and Moderate Leverage
13 Healthy Operating Cash and Moderate Leverage EBITDA* (NT$mn) EBITDA Margin(%) Pro-forma** NET DEBT/LTM EBITDA (x) 45 2.97 31 2,654 2,138 0.78 1Q25 1Q26 1Q25 1Q26 1Q25 1Q26 *EBITDA =EBIT + Depreciation + Amortization + Impairment + Shared Based Payment ** Pro-forma includes Apr-Nov 2025 EBTIDA for
Slide 14: Business Update
03 | nf : BUSINESS i UPDATE
Slide 15: 2026 Key Strategic Priorities Remain On Track
15 2026 Key Strategic Priorities Remain On Track 1 4 Strong Start from Alvogen Integration Executing on Integration Synergies • Full-quarter contribution as main driver of • Driving value realisation across key functions Group’s 83% YoY growth following Alvogen integration 2 5 B2B Momentum from Key
Slide 16: An international pharmaceutical company with global presence
An international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines https://www.lotuspharm.com.tw/ +886 2 2700 5908 info@lotuspharm.com in www.linkedin.com/company/lotus-pharmaceutica